{"entity":{"id":"paper-aspen-armstrong-lancet-oncol-2016","kind":"paper","name":"ASPEN: everolimus versus sunitinib in metastatic non-clear cell renal cell carcinoma","aka":[],"tldr":"In the first randomised trial dedicated to non-clear cell kidney cancers, sunitinib delayed progression more than everolimus overall, though chromophobe tumours appeared to fare better on everolimus.","summary":"Randomised phase 2 trial of 108 patients with metastatic papillary, chromophobe or unclassified renal cell carcinoma randomised to sunitinib or everolimus.\n\nMedian progression-free survival was 8.3 months with sunitinib against 5.6 months with everolimus (hazard ratio 1.41 for everolimus); in the small chromophobe subgroup everolimus gave longer progression-free survival (11.4 versus 5.5 months), while papillary tumours did better with sunitinib.","asOf":"2026-09-17","links":[{"label":"Lancet Oncol 2016","url":"https://doi.org/10.1016/S1470-2045(15)00515-X"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/26794930/"}],"tags":[],"related":[],"cancers":["chromophobe-rcc","papillary-rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["everolimus","sunitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2016,"doi":"10.1016/S1470-2045(15)00515-X","pmid":"26794930","authors":"Armstrong AJ, Halabi S, Eisen T, et al.","paperType":"rct","findings":["Median progression-free survival 8.3 months (sunitinib) vs 5.6 months (everolimus).","Chromophobe subgroup: 11.4 months with everolimus vs 5.5 months with sunitinib."],"whatItMeans":"VEGF-directed therapy is the default for non-clear cell disease, with everolimus considered in chromophobe tumours; cabozantinib later became preferred for papillary disease.","caveats":["Small heterogeneous trial; subgroup findings are hypothesis-generating."],"changedPractice":true,"participants":108},"route":"/key-papers/paper-aspen-armstrong-lancet-oncol-2016/","neighbours":{"cancer":[{"id":"chromophobe-rcc","kind":"cancer","name":"Chromophobe renal cell carcinoma","route":"/cancers/chromophobe-rcc/"},{"id":"papillary-rcc","kind":"cancer","name":"Papillary renal cell carcinoma","route":"/cancers/papillary-rcc/"}],"drug":[{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}